Crizotinib, a tyrosine kinase inhibitor (TKI) targeting ALK, ROS1 as well as MET, was the first drug approved by the Food and Drug Administration (FDA) for patients with advanced ALK-rearranged or ROS1-rearranged NSCLC. Here, ALK is linked to non-small cell lung carcinoma.